Sha Hua

Sha Hua

Auto-generated profile, based on publicly available information

Sha Hua

Department of Cardiovascular Medicine Heart Failure Center, RuiJin Hospital LuWan Branch, Shanghai Jiao Tong University School of Medicine Shanghai China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
ZQZeping Qiu
Zeping Qiu
YFYingze Fan
Yingze Fan
ZWZhiyan Wang
Zhiyan Wang
FHFanyi Huang
Fanyi Huang
ZLZhuojin Li
Zhuojin Li
YCYanjia Chen
Yanjia Chen
Background: Catestatin has been reported as a pleiotropic cardioprotective peptide. Heart failure with preserved ejection fraction (HFpEF) was considered a heterogeneous syndrome with a complex cause. We sought to investigate the role of catestatin in HFpEF and diastolic dysfunction. METHODS AND RESULTS: Administration of recombinant catestatin (1.5 mg/kg/d) improved diastolic dysfunction and left ventricular chamber stiffness in transverse aortic constriction mice with deoxycorticosterone acetate pellet implantation, as reflected by Doppler tissue imaging and pressure‐volume loop catheter. Less cardiac hypertrophy and myocardial fibrosis was observed, and transcriptomic analysis revealed downregulation of mitochondrial electron transport chain components after catestatin treatment. Catestatin reversed mitochondrial structural and respiratory chain component abnormality, decreased mitochondrial proton leak, and reactive oxygen species generation in myocardium. Excessive oxidative stress induced by Ru360 abolished catestatin treatment effects on HFpEF‐like cardiomyocytes in vitro, indicating the beneficial role of catestatin in HFpEF as a mitochondrial ETC modulator. The serum concentration of catestatin was tested among 81 patients with HFpEF and 76 non–heart failure controls. Compared with control subjects, serum catestatin concentration was higher in patients with HFpEF and positively correlated with E velocity to mitral annular e′ velocity ratio, indicating a feedback compensation role of catestatin in HFpEF. Conclusions: Catestatin protects against diastolic dysfunction in HFpEF through attenuating mitochondrial electron transport chain–derived reactive oxygen species generation. Serum catestatin concentration is elevated in patients with HFpEF, probably as a relatively insufficient but self‐compensatory mechanism.

11 April 2018 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SHSha Hua
Sha Hua
CMChuanxiang Ma
Chuanxiang Ma
JZJun Zhang
Jun Zhang
JLJing Li
Jing Li
WWWeiwei Wu
Weiwei Wu
JZJianrong Zhao
Jianrong Zhao
Pharmacogenetics or pharmacogenomics approaches are important for addressing the individual variabilities of drug efficacy especially in the era of precision medicine. One particular interesting gene to investigate is APOA5, which has been repeatedly linked with the inter-individual variations of serum triglycerides. Here, we explored APOA5-statin interactions in 195 Chinese subjects randomized to rosuvastatin (5–10 mg/day), atorvastatin (10–20 mg/day), or simvastatin (40 mg/day) for 12 weeks by performing a targeted genotyping analysis of the APOA5 promoter SNP rs662799 (-1131T > C). There were no significant differences between the treatment arms for any of the statin-induced changes in clinical biomarkers. Reductions in LDL cholesterol were influenced by the APOA5 genotype in all three treatment groups. By contrast, changes in HDL cholesterol, and triglycerides were only affected by the APOA5 genotype in the atorvastatin and simvastatin groups and not in the rosuvastatin group. Our results suggest that future studies may need to consider stratifying subjects not only by genetic background but also by prescribed statin type.

27 August 2024 in Phenomics
Verified
Journal Article
Closed access
PDF file
CWChengyan Wang
Chengyan Wang
SWShuo Wang
Shuo Wang
SHSha Hua
Sha Hua
RLRuokun Li
Ruokun Li
YLYan Li
Yan Li
MTMei Tian
Mei Tian

22 January 2026 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
YGYiwen Gong
Yiwen Gong
HQHaikun Qi
Haikun Qi
SHSha Hua
Sha Hua